Breast Cancer Consensus Meetings: Vive la Difference? Journal Articles

authors

• Davidson, Nancy E
• Levine, Mark Norman

status

• published 

publication date

• April 1, 2002

has subject area

• 1103 Clinical Sciences (FoR)
• 1112 Oncology and Carcinogenesis (FoR)
• Antineoplastic Agents, Hormonal (MeSH)
• Antineoplastic Combined Chemotherapy Protocols (MeSH)
• Breast Neoplasms (MeSH)
• Combined Modality Therapy (MeSH)
• Consensus Development Conferences as Topic (MeSH)
• Europe (MeSH)
• Evidence-Based Medicine (MeSH)
• Female (MeSH)
• Gonadotropin-Releasing Hormone (MeSH)
• Humans (MeSH)
• Neoplasm Staging (MeSH)
• Neoplasms, Hormone-Dependent (MeSH)
• Oncology & Carcinogenesis (Science Metrix)
• Ovary (MeSH)
• Practice Guidelines as Topic (MeSH)
• Randomized Controlled Trials as Topic (MeSH)
• Tamoxifen (MeSH)
• United States (MeSH)

published in

• Journal of Clinical Oncology  Journal

keywords

• Antineoplastic Agents, Hormonal
• Antineoplastic Combined Chemotherapy Protocols
• Breast Neoplasms
• Combined Modality Therapy
• Consensus Development Conferences as Topic
• Europe
• Evidence-Based Medicine
• Female
• Gonadotropin-Releasing Hormone
• Humans
• Neoplasm Staging
• Neoplasms, Hormone-Dependent
• Ovary
• Practice Guidelines as Topic
• Randomized Controlled Trials as Topic
• Tamoxifen
• United States

Digital Object Identifier (DOI)

• 10.1200/jco.2002.20.7.1719

PubMed ID

• 11919226

start page

• 1719

end page

• 1920

volume

• 20

issue

• 7